Incyte (INCY) PT Raised to $113 at RBC
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
RBC Capital analyst Simos Simeonidis reiterated an Outperform rating and boosted his price target on Incyte (NASDAQ: INCY) to $113.00 (from $106.00) following the epacadostat update at ESMO
Simeonidis commented, "Despite what we acknowledge is a small sample size, and the fact that we’ve only seen very strong evidence of its activity and safety in one tumor type (melanoma), we remain impressed by the data and are thus raising the probability of success for the drug in this indication."
Shares of Incyte closed at $92.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Starts Incyte (INCY) at Outperform, Says Jakafi Growth & Pipeline Expansion + Scarity Drives Bullish View
- Teradyne (TER) PT Raised to $28 at Deutsche Bank; Reiterates Buy
- UPDATE: Instinet Downgrades Qualcomm (QCOM) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!